Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp
- 1 October 1997
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 41 (10), 2310-2311
- https://doi.org/10.1128/aac.41.10.2310
Abstract
The in vitro activity of Schering 56592, a new azole drug, was compared with those of fluconazole and itraconazole against 103 isolates of Candida comprising 10 different species. Schering 56592 was more active than itraconazole and fluconazole, and it was active against many fluconazole-resistant isolates.Keywords
This publication has 6 references indexed in Scilit:
- Can we prevent azole resistance in fungi?The Lancet, 1995
- Patterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from SpainAntimicrobial Agents and Chemotherapy, 1995
- Emergence of azole drug resistance in Candida species from HIV-infected patients receivingprolonged fluconazole therapy for oral candidosisJournal of Antimicrobial Chemotherapy, 1995
- High prevalence of antifungal resistance in Candida spp. from patients with AIDSJournal of Antimicrobial Chemotherapy, 1994
- Fluconazole-resistant candidosis in an HIV cohortAIDS, 1994
- Improved medium for fluconazole susceptibility testing of Candida albicansAntimicrobial Agents and Chemotherapy, 1994